Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03832907 · ClinicalTrials.gov registry record · NA
Dexcom G6 Observational Study
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 101
- Enrollment target
NCT03832907: Completed NA study, sponsored by Emory University.
NCT03832907 is a NA study that has completed, run by Emory University. The registered enrollment target is 101 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03832907, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 101 participants
- Enrollment target
Study Summary
This is an exploratory prospective study primary aiming to evaluate differences between Point-of-care (POC) testing (standard of care) and Dexcom G6 CGM (Continues Glucose Monitoring sensor system) in 1) glycemic control measured by mean daily blood glucose and 2) identifying hypoglycemic and hyperglycemic events - in patients with type 1 and type 2 diabetes treated with basal bolus insulin regimen.
Primary Outcome
Mean daily blood glucose will be calculated
Interventions
- DEVICE Dexcom G6 CGM - Continues Glucose Monitoring sensor system
- DIAGNOSTIC_TEST POC BG - Point-of-Care Blood Glucose monitoring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2019-02-21 |
| Est. Completion | 2020-03-31 |
| Phase | NA |
What the finished NCT03832907 record still lists
NCT03832907 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Dexcom G6 CGM - Continues Glucose Monitoring sensor system is the first listed.
NCT03832907 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03832907 about?
NCT03832907 is a clinical study titled "Dexcom G6 Observational Study". This is an exploratory prospective study primary aiming to evaluate differences between Point-of-care (POC) testing (standard of care) and Dexcom G6 CGM (Continues Glucose Monitoring sensor system) in 1) glycemic control measured by mean daily blood glucose and 2) identifying hypoglycemic and hyperg...
What is the current status of trial NCT03832907?
This trial is currently completed. It is a NA study. The enrollment target is 101 participants. The study started on 2019-02-21. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT03832907?
The interventions under investigation include: Dexcom G6 CGM - Continues Glucose Monitoring sensor system (DEVICE), POC BG - Point-of-Care Blood Glucose monitoring (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03832907?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03832907's enrollment target sits among peer trials
101 840th of 2000 higher than 1,161 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI